Dorsomedial prefrontal theta burst stimulation to treat anhedonia, avolition, and blunted affect in schizophrenia or depression – a randomized controlled trial
| Autor: | Robert Bodén, Elin Thörnblom, W. Struckmann, Jonas Persson, Johan Bengtsson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Anhedonia
Prefrontal Cortex Transcutaneous electrical nerve stimulation Psykiatri law.invention Depressive Disorder Treatment-Resistant 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans Theta Rhythm Adverse effect Avolition Depression (differential diagnoses) Psychiatry Depression business.industry iTBS repetitive transcranial magnetic stimulation medicine.disease Transcranial Magnetic Stimulation 030227 psychiatry anhedonia Psychiatry and Mental health Clinical Psychology Schizophrenia Anesthesia motivational deficit Blunted Affect double-blind medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Affective Disorders. 290:308-315 |
| ISSN: | 0165-0327 |
| DOI: | 10.1016/j.jad.2021.04.053 |
| Popis: | Background Intermittent theta burst stimulation (iTBS) over the dorsomedial prefrontal cortex (DMPFC) has shown promise in open-label trials of depression. Methods In this randomized, double-blind, sham controlled trial we evaluate iTBS over the DMPFC for anhedonia, avolition, and blunted affect in patients with schizophrenia or depression. Active iTBS was delivered over the DMPFC with 1200 pulses per session, twice daily over ten weekdays at target intensity with an angled figure-of eight coil. Sham condition comprised the magnetically shielded side of the coil and simultaneous transcutaneous electrical nerve stimulation. Primary outcome was change on the Clinical Assessment Interview for Negative Symptoms (CAINS). Results Twenty-eight patients were randomized to active iTBS and 28 to sham. Mean (standard deviation) change in CAINS score from baseline to the day after last treatment was -5.3 (8.1) in active iTBS and -2.1 (7.1) in sham. A linear model showed no significant effect of treatment, accounting for baseline scores p=.088. Sub analyses per diagnostic group showed a significant effect in patients with depression, p=.038, but not in the schizophrenia group, p=.850. However, overall depressive symptoms did not change significantly in patients with depression. There were three serious adverse events, all in the sham group. Limitations Possibly too short treatment course and few patients with schizophrenia. Conclusion In this first transdiagnostic randomized controlled trial of iTBS over DMPFC for anhedonia, avolition, and blunted affect it can be concluded that it was generally tolerable and safe but only more effective than sham in the subgroup of patients with depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect